Gamifant
Payments companies reported to CMS as associated with Gamifant. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Gamifant, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Gamifant
These are the largest totals companies reported as associated with Gamifant. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Ashish Kumar | Cincinnati, OH | Pediatric Hematology-Oncology | $189,594.43 |
| Jaap Jan Boelens | New York, NY | Pediatric Hematology-Oncology | $175,693.96 |
| Saara Kaviany | New York, NY | Pediatric Hematology-Oncology | $124,244.75 |
| Eric Halstead | Hershey, PA | Pediatric Critical Care Medicine | $98,410.49 |
| George Yaghmour | Los Angeles, CA | Hematology & Oncology | $77,663.44 |
| Rikin Shah | Oklahoma City, OK | Pediatric Hematology-Oncology | $66,629.23 |
| Jessie Alexander | Palo Alto, CA | Pediatric Hematology-Oncology | $62,104.74 |
| William Johnson | New York, NY | Hematology & Oncology | $59,750.49 |
| Joseph Oved | New York, NY | Pediatric Hematology-Oncology | $58,243.48 |
| Edward Behrens | Philadelphia, PA | Pediatric Rheumatology | $55,010.96 |
Prescribed Gamifant?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.